Alkermes and Indevus Start Pulmonary Disease Study
Posted on: Wednesday, 25 April 2007, 15:00 CDT
Alkermes and Indevus Pharmaceuticals have started a phase IIa study of ALKS 27 in patients with chronic obstructive pulmonary disease.
ALKS 27 is an inhaled formulation of trospium chloride based on Alkermes' AIR pulmonary technology. The study will assess the safety, tolerability, pharmacokinetics and efficacy of single doses of ALKS 27.
As an inhaled formulation of trospium chloride, a muscarinic receptor antagonist that relaxes smooth muscle tissue, the companies believe ALKS 27 could potentially improve airflow and provide a new treatment option for patients with chronic obstructive pulmonary disease (COPD).
"By combining our proprietary AIR technology and Indevus' trospium chloride, a molecule with a known safety profile and proven efficacy in an approved indication, we hope to bring forward a more patient-friendly treatment option for people with COPD," stated Elliot Ehrich, chief medical officer of Alkermes.
The efficacy of ALKS 27 will be evaluated based on improvements in pulmonary function in patients with COPD. This phase IIa study follows completion of a phase I study which demonstrated that ALKS 27 was well tolerated over a wide dose range, with no dose-limiting effects observed. Alkermes and Indevus expect to report results from the study in the second half of 2007.
Source: Datamonitor
Related Articles
- Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
- Elan and Transition Therapeutics Achieve Patient Enrollment Target in Phase 2 Clinical Study of ELND005 (AZD-103) in Alzheimer's Disease
- Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
- Depomed Reports Positive Efficacy Data From a Phase 2 Trial of Gabapentin GR(TM) in the Treatment of Menopausal Hot Flashes
- Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
- Keryx Biopharmaceuticals Announces Completion of Patient Randomization Into Sulonex Phase III Pivotal Study
- Medivation Exceeds Patient Enrollment Target in Phase 2 Alzheimer's Disease Trial
- Altus Pharmaceuticals Presents Results From ALTU-135 (TheraCLEC(TM)) Phase II Study in Cystic Fibrosis Patients With Pancreatic Insufficiency
- A Pilot Study of the Safety and Efficacy of Tobramycin Solution for Inhalation in Patients With Severe Bronchiectasis*
- Genmab A/S and Medarex Announce Positive Safety and Efficacy Data in Phase I/II Trial With HuMax-Inflam/MDX-018
 |
 |
User Comments (0)
RSS Feeds